Baddipadige Raju, Gera Narendra, Himanshu Verma, Manoj Kumar, Bharti Sapra, Gurleen Kaur, Subheet Kumar Jain, Padakanti Sandeep Chary, Neelesh Kumar Mehra, Om Silakari
Cytochrome P450 1B1, a tumor-specific overexpressed enzyme, significantly impairs the pharmacokinetics of several commonly used anticancer drugs including docetaxel, paclitaxel and cisplatin, leading to the problem of resistance to these drugs. Currently, there is no CYP1B1 inhibition-based adjuvant therapy available to treat this resistance problem. Hence, in the current study, exhaustive in-silico studies including scaffold hopping followed by molecular docking, three-dimensional quantitative structure-activity relationships (3D-QSAR), molecular dynamics and free energy perturbation studies were carried out to identify potent and selective CYP1B1 inhibitors...
February 14, 2024: Journal of Biomolecular Structure & Dynamics